122 related articles for article (PubMed ID: 33647870)
1. Tamoxifen. A treatment for meningioma?
Champeaux-Depond C; Weller J
Cancer Treat Res Commun; 2021; 27():100343. PubMed ID: 33647870
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis type 2: A nationwide population-based study focused on survival after meningioma surgery.
Champeaux-Depond C; Weller J; Resche-Rigon M
Clin Neurol Neurosurg; 2020 Nov; 198():106236. PubMed ID: 33002675
[TBL] [Abstract][Full Text] [Related]
3. Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study.
Champeaux-Depond C; Constantinou P; Weller J
World Neurosurg; 2021 Feb; 146():e67-e75. PubMed ID: 33096279
[TBL] [Abstract][Full Text] [Related]
4. A nationwide population-based study on overall survival after meningioma surgery.
Champeaux-Depond C; Weller J; Froelich S; Resche-Rigon M
Cancer Epidemiol; 2021 Feb; 70():101875. PubMed ID: 33360358
[TBL] [Abstract][Full Text] [Related]
5. Atypical meningioma. A study on recurrence and disease-specific survival.
Champeaux C; Houston D; Dunn L
Neurochirurgie; 2017 Sep; 63(4):273-281. PubMed ID: 28882609
[TBL] [Abstract][Full Text] [Related]
6. Cyproterone acetate and meningioma: a nationwide-wide population based study.
Champeaux-Depond C; Weller J; Froelich S; Sartor A
J Neurooncol; 2021 Jan; 151(2):331-338. PubMed ID: 33394263
[TBL] [Abstract][Full Text] [Related]
7. Outcome After Protontherapy for Progression or Recurrence of Surgically Treated Meningioma.
Champeaux-Depond C; Weller J
Brain Tumor Res Treat; 2021 Oct; 9(2):46-57. PubMed ID: 34725984
[TBL] [Abstract][Full Text] [Related]
8. Histological transformation in recurrent WHO grade I meningiomas.
Corniola MV; Lemée JM; Meling TR
Sci Rep; 2020 Jul; 10(1):11220. PubMed ID: 32641701
[TBL] [Abstract][Full Text] [Related]
9. World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment.
Champeaux C; Jecko V
Neurochirurgie; 2016 Aug; 62(4):203-8. PubMed ID: 27339832
[TBL] [Abstract][Full Text] [Related]
10. Clear Cell Meningioma: A Clinicopathologic Study of a Rare Meningioma Subtype in 35 Patients.
Soni P; Li S; Sagar S; Prayson RA; Angelov L; Mohammadi AM; Barnett GH; Recinos PF; Kshettry VR
World Neurosurg; 2020 Sep; 141():e334-e340. PubMed ID: 32445901
[TBL] [Abstract][Full Text] [Related]
11. Malignant Meningioma: An International Multicentre Retrospective Study.
Champeaux C; Jecko V; Houston D; Thorne L; Dunn L; Fersht N; Khan AA; Resche-Rigon M
Neurosurgery; 2019 Sep; 85(3):E461-E469. PubMed ID: 30566646
[TBL] [Abstract][Full Text] [Related]
12. Recurrence Interval Within 1 Year Leads to Death in Patients with Grade 2 Meningioma.
Ukai R; Wanibuchi M; Komatsu K; Kimura Y; Akiyama Y; Mikami T; Mikuni N
World Neurosurg; 2020 Oct; 142():e58-e65. PubMed ID: 32454195
[TBL] [Abstract][Full Text] [Related]
13. Multimodal Management of Metastatic Malignant Meningiomas: The Role of Radiosurgery in Long-Term Local Control.
Attuati L; Zaed I; Morselli C; Pecchioli G; Fornari M; Picozzi P
World Neurosurg; 2019 Aug; 128():562-572. PubMed ID: 31102770
[TBL] [Abstract][Full Text] [Related]
14. Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy.
Chen WC; Magill ST; Wu A; Vasudevan HN; Morin O; Aghi MK; Theodosopoulos PV; Perry A; McDermott MW; Sneed PK; Braunstein SE; Raleigh DR
J Neurosurg; 2018 Apr; 130(2):443-450. PubMed ID: 29624151
[TBL] [Abstract][Full Text] [Related]
15. Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit.
Pant S; Tonse R; Kannan S; Moiyadi A; Shetty P; Epari S; Sahay A; Sastri GJ; Jalali R; Gupta T
Pract Radiat Oncol; 2018; 8(5):e275-e284. PubMed ID: 29861352
[TBL] [Abstract][Full Text] [Related]
16. Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series.
Pessina F; Navarria P; Clerici E; Soffietti R; Nibali MC; Rudà R; Riva M; Scorsetti M; Bello L
World Neurosurg; 2019 Mar; 123():e273-e279. PubMed ID: 30496926
[TBL] [Abstract][Full Text] [Related]
17. World Health Organization Grade III (Nonanaplastic) Meningioma: Experience in a Series of 23 Cases.
Zhang GJ; Zhang GB; Zhang YS; Li H; Li CB; Zhang LW; Li D; Wu Z; Zhang JT
World Neurosurg; 2018 Apr; 112():e754-e762. PubMed ID: 29382616
[TBL] [Abstract][Full Text] [Related]
18. Clear cell histology portends a worse prognosis than other WHO grade II histologies.
Soni P; Shao J; Momin A; Lopez D; Angelov L; Mohammadi AM; Barnett GH; Recinos PF; Kshettry VR
J Neurooncol; 2021 Jan; 151(2):307-312. PubMed ID: 33398533
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of meningiomas. A nationwide study of surgically treated tumours on French medico-administrative data.
Champeaux C; Weller J; Katsahian S
Cancer Epidemiol; 2019 Feb; 58():63-70. PubMed ID: 30481723
[TBL] [Abstract][Full Text] [Related]
20. WHO grade II and III meningiomas: a study of prognostic factors.
Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
